This biographical article is written like a résumé .(July 2020) |
Gitte Moos Knudsen | |
---|---|
Born | Lyngby, Denmark | 15 February 1959
Education | University of Copenhagen, Rigshospitalet, NIH, MGH |
Known for | neurobiology of neurotransmission, with particular emphasis on molecular brain imaging |
Medical career | |
Profession | Neurologist |
Institutions | University of Copenhagen; CIMBI, |
Sub-specialties | brain imaging Neurotransmitters |
Research | neurotransmission, particularly serotonin |
Awards | Niels Lassen Prize Synthelabo RechercheAward Monrad-Krohn Prize for the Advancement of Neurological Research |
Gitte Moos Knudsen (legal name Karen Birgitte Moos Knudsen) is a Danish translational neurobiologist and clinical neurologist, and Clinical Professor and Chief Physician at the Department of Clinical Medicine, Neurology, Psychiatry and Sensory Sciences, at Copenhagen University Hospital. [1] She graduated from Lyngby Statsskole, just north of Copenhagen, before gaining entrance to medicine, where she received her MD from University of Copenhagen in 1984, and became a Board certified user of radioisotopes in 1986. She sat the FMGEMS exam (Foreign Medical Graduates Examination in the Medical Sciences) (US) in 1989. She became Board certified in neurology in 1994 and received her DMSc (Dr.Med.) from University of Copenhagen in 1994. She currently resides in Copenhagen, and is married to Tore Vulpius. She has 3 children.
Knudsen is one of the leading figures in the neurosciences, assisting various European Union nations to prioritize research and grants. In addition, her research into the brain and its chemistry during depression, Alzheimer's disease, and states induced by drugs such as GHB and ecstasy (MDMA) is at the forefront of world knowledge, and she is a noted scholar in these areas, publishing many papers on each topic. Her interest in brain imaging has led to a deeper understanding of how many receptors act within the brain, and she has produced studies using SPECT, PET, and MRI results to interpret these. A key issue is that the latest brain research not only contributes to increased understanding of brain functions, but is also used to attempt to explain what it means to be human. [2]
The Lundbeck Foundation, created in 1954, donated one of the largest amounts ever given toward the development of medical knowledge, listing a total of DKK 504 million to various institutions in 2011. [3] With a 40 million grant from this program, Knudsen, together with a team of researchers from the Center for Integrated Molecular Imaging of the Brain (CIMBI), [4] University of Copenhagen, are concentrating on investigating the neural bases of personality that predispose individuals to various disorders, using PET and MRI technology. She is currently the Center Director of The Lundbeck Foundation Centre for Integrated Molecular Brain Imaging (CIMBI). [5]
Regarding her research, Knudsen states:
I am a translational neurobiologist and clinical neurologist with interest in advanced methodological developments that I subsequently apply in my research to address pertinent neurobiological and clinical issues. My scientific interests have fallen in three sequentially separated categories:
H. Lundbeck A/S is a Danish international pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at brain diseases, including depression, schizophrenia, Alzheimer's disease, Parkinson's disease and migraine.
Rigshospitalet is the largest public and teaching hospital in Copenhagen and the most highly specialised hospital in Denmark. The hospital's main building is a 16-storey functionalist highrise, one of the tallest structures in the central parts of the city. Rigshospitalet neighbours the Panum Building which houses the Faculty of Health and Medical Sciences at the University of Copenhagen. As a teaching hospital it is part of the framework organisation Copenhagen University Hospital.
Cerebral amyloid angiopathy (CAA) is a form of angiopathy in which amyloid beta peptide deposits in the walls of small to medium blood vessels of the central nervous system and meninges. The term congophilic is sometimes used because the presence of the abnormal aggregations of amyloid can be demonstrated by microscopic examination of brain tissue after staining with Congo red. The amyloid material is only found in the brain and as such the disease is not related to other forms of amyloidosis.
Desmoteplase is a novel, highly fibrin-specific "clot-busting" (thrombolytic) drug in development that reached phase III clinical trials. The Danish pharmaceutical company, Lundbeck, owns the worldwide rights to Desmoteplase. In 2009, two large trials were started to test it as a safe and effective treatment for patients with acute ischaemic stroke. After disappointing results in DIAS-3, DIAS-4 was terminated, and in December 2014 Lundbeck announced that they would stop the development of desmoteplase.
Neuroimaging is the use of quantitative (computational) techniques to study the structure and function of the central nervous system, developed as an objective way of scientifically studying the healthy human brain in a non-invasive manner. Increasingly it is also being used for quantitative studies of brain disease and psychiatric illness. Neuroimaging is a highly multidisciplinary research field and is not a medical specialty.
Niels Alexander Lassen was a Danish nuclear medicine physician, neurologist and pioneer in the fields of neuroimaging, neuropsychiatry and nuclear medicine. He was born and died in Copenhagen.
Olaf Bjarne Paulson is a Danish neuroscientist.
Transferrin receptor protein 1 (TfR1), also known as Cluster of Differentiation 71 (CD71), is a protein that in humans is encoded by the TFRC gene. TfR1 is required for iron import from transferrin into cells by endocytosis.
Altanserin is a compound that binds to the 5-HT2A receptor. Labeled with the isotope fluorine-18 it is used as a radioligand in positron emission tomography (PET) studies of the brain, i.e., studies of the 5-HT2A neuroreceptors. Besides human neuroimaging studies altanserin has also been used in the study of rats.
Droxidopa is a synthetic amino acid precursor which acts as a prodrug to the neurotransmitter norepinephrine (noradrenaline). Unlike norepinephrine, droxidopa is capable of crossing the protective blood–brain barrier (BBB).
Rigshospitalet Glostrup is located in the township of Glostrup 8 km from the center of Copenhagen in Denmark. It is owned and managed by the regional health authority of the Greater Copenhagen region, Region Hovedstaden. The hospital was formerly known as Glostrup Hospital, but after the merger with Rigshospitalet 1/1/2015, it is now known as Rigshospitalet Glostrup.
25B-NBOMe is a derivative of the phenethylamine psychedelic 2C-B, discovered in 2004 by Ralf Heim at the Free University of Berlin. It acts as a potent full agonist for the 5HT2A receptor. Anecdotal reports from users suggest 25B-NBOMe to be an active hallucinogen at a dose of as little as 250–500 µg, making it a similar potency to other phenethylamine derived hallucinogens such as Bromo-DragonFLY. Duration of effects lasts about 12–16 hours, although the parent compound is rapidly cleared from the blood when used in the radiolabeled form in tracer doses. Recently, Custodio et al (2019) evaluated the potential involvement of dysregulated dopaminergic system, neuroadaptation, and brain wave changes which may contribute to the rewarding and reinforcing properties of 25B-NBOMe in rodents.
Albert Gjedde: is a Danish-Canadian neuroscientist. He is Professor of Neurobiology and Pharmacology at the Faculty of Health Sciences and Center of Neuroscience at the University of Copenhagen. He is currently also Adjunct Professor of Neurology and Neurosurgery in the Department of Neurology, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada, Adjunct Professor of Radiology and Radiological Science in the Division of Nuclear Medicine, Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland, US, Adjunct Professor of Translational Neuropsychiatry Research, University of Southern Denmark, Odense, Denmark, and adjunct professor of psychiatry at Tabriz University of Medical Sciences, Tabriz, East Azerbadjan, Iran.
The European College of Neuropsychopharmacology (ECNP) is a pan-European, non-profit scientific association that serves as a platform to exchange and promote research in the field of neuropsychopharmacology. The ECNP “is committed to ensuring that advances in the understanding of brain function and human behaviour are translated into better treatments and enhanced public health”. The ECNP organises a number of activities to achieve this aim, such as a yearly congress, workshops, seminars, New Frontiers Meetings, publications, awards, supported talks and much more.
The following outline is provided as an overview of and topical guide to brain mapping:
Andreas Kjær is a Danish physician-scientist and European Research Council (ERC) advanced grantee. He is professor at the University of Copenhagen and chief physician at Rigshospitalet, the National University Hospital of Denmark. He is board certified in Nuclear Medicine and his research is focused on molecular imaging with PET and PET/MRI and targeted radionuclide therapies (theranostics) in cancer. His achievements include development of several new PET tracers that have reached first-in-human clinical use. He has published more than 400 peer-review articles, filed 10 patents, supervised more than 40 PhD students and received numerous prestigious scientific awards over the years. He is a member of the Danish Academy of Technical Sciences
Messoud Ashina is a Danish-Azerbaijani neurologist and neuroscientist. He is currently a Professor of Neurology at the University of Copenhagen and leads the Human Migraine Research Unit at the Danish Headache Center, Rigshospitalet. Ashina is also the Director of the Danish Knowledge Center on Headache Disorders and the past President of the International Headache Society. As of 2022, Ashina is ranked as the world's leading expert on headache disorders by Expertscape.
Martin Johannes Lauritzen is a Danish neuroscientist. He is Professor of Translational Neurobiology at the Department of Neuroscience, University of Copenhagen, Denmark and Professor of Clinical Neurophysiology at the Department of Neurophysiology, Rigshospitalet.
Martina F. Callaghan is an Irish medical physicist who is the Director of the Wellcome Centre for Human Neuroimaging at the UCL Queen Square Institute of Neurology. Her research considers the development of in-vivo histology using MRI.
A cerebroprotectant is a drug that is intended to protect the brain after the onset of acute ischemic stroke. As stroke is the second largest cause of death worldwide and a leading cause of adult disability, over 150 drugs tested in clinical trials to provide cerebroprotection.